dc.contributor.author | Reckamp, KL | |
dc.contributor.author | Lin, HM | |
dc.contributor.author | Cranmer, H | |
dc.contributor.author | Wu, Y | |
dc.contributor.author | Zhang, P | |
dc.contributor.author | Kay, S | |
dc.contributor.author | Walton, LJ | |
dc.contributor.author | Shen, J | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Camidge, DR | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-10-05T13:17:59Z | |
dc.date.available | 2022-10-05T13:17:59Z | |
dc.date.issued | 2022-07-28 | |
dc.identifier.citation | Current Medical Research and Opinion, 2022, 38 (9), pp. 1587 - 1593 | en_US |
dc.identifier.issn | 0300-7995 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5521 | |
dc.identifier.eissn | 1473-4877 | |
dc.identifier.eissn | 1473-4877 | |
dc.identifier.doi | 10.1080/03007995.2022.2100653 | |
dc.description.abstract | BACKGROUND: Second-generation anaplastic lymphoma kinase (ALK) gene targeted tyrosine kinase inhibitors (TKIs) alectinib and brigatinib have shown efficacy as front-line treatments for ALK-positive non-small cell lung cancer (NSCLC). No head-to-head data are currently available for brigatinib vs alectinib in the ALK-TKI-naive population. OBJECTIVE: To estimate the relative overall survival (OS) for brigatinib vs alectinib with indirect treatment comparisons (ITCs) using ALEX and ALTA-1L clinical trial data. METHODS: The latest aggregate data from the ALEX trial and final patient-level data from ALTA-1L were used. ITCs were conducted with/without treatment crossover adjustments to estimate relative OS. Bucher methods, anchored matching-adjusted indirect comparisons (MAICs) and unanchored MAICs were employed in ITCs without treatment crossover adjustments. An inverse probability of censoring weight Cox model, a marginal structure model and rank-preserving structural failure time models (with/without re-censoring) within an anchored MAIC were used in ITCs with treatment crossover adjustments. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported. RESULTS: HRs for brigatinib vs alectinib for relative OS generated from ITCs without treatment crossover adjustments ranged from 0.90 (95% CI: 0.59-1.38) in the unanchored MAIC to 1.20 (95% CI: 0.69-2.11) using the Bucher method. Methods employing treatment switching adjustments estimated HRs for relative OS ranging from 0.74 (95% CI: 0.38-1.45) to 1.11 (95% CI: 0.63-1.94). Results from all ITCs did not indicate statistically different survival profiles. CONCLUSION: Regardless of ITC methodology, OS is comparable for brigatinib vs alectinib in patients with ALK+ NSCLC previously untreated with an ALK inhibitor. | |
dc.format | Print-Electronic | |
dc.format.extent | 1587 - 1593 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | TAYLOR & FRANCIS LTD | en_US |
dc.relation.ispartof | Current Medical Research and Opinion | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | ALK+ NSCLC | |
dc.subject | alectinib | |
dc.subject | brigatinib | |
dc.subject | indirect treatment comparison | |
dc.subject | overall survival | |
dc.subject | Anaplastic Lymphoma Kinase | |
dc.subject | Carbazoles | |
dc.subject | Carcinoma, Non-Small-Cell Lung | |
dc.subject | Crizotinib | |
dc.subject | Humans | |
dc.subject | Lung Neoplasms | |
dc.subject | Organophosphorus Compounds | |
dc.subject | Piperidines | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Pyrimidines | |
dc.title | Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-07-08 | |
dc.date.updated | 2022-10-05T13:17:19Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1080/03007995.2022.2100653 | en_US |
rioxxterms.licenseref.startdate | 2022-07-28 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35815801 | |
pubs.issue | 9 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1080/03007995.2022.2100653 | |
pubs.volume | 38 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman on 2022-10-05. Deposit type is initial. No. of files: 1. Files: Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front line anaplastic lymphoma kinase positive.pdf | |